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Pathogenesis of ascites and hepatorenal syndrome
S P Wilkinson, K P Moore, V Arroyo
Ascites is one of the most common complications
of cirrhosis and has a one year mortality of up to
50%. For fluid to accumulate in any clinical
situation the amount of sodium ingested must
exceed that excreted by the kidneys and the
virtual absence of sodium from the urine of
ascitic patients was first documented by Farns-
worth and Krakusin in 1948.' Five years later
Chart and Shipley showed such patients to have
an excess of a sodium retaining hormone in their
urine (later identified as aldosterone).2 Four
decades after these discoveries the inter-relation-
ship between renal function, hormonal changes
and ascites formation remains controversial. At
the other extreme of functional renal changes up
to 85% ofpatients dying with cirrhosis have renal
failure and, where there is no apparent cause
other than the liver disease, is termed 'hepato-
renal syndrome.' In 1863 Flint noted that pro-
teinuria was uncommon and kidney morphology
often normal, but some patients showed a variety
of renal parenchymal changes.3 Hecker and
Sherlock confirmed the absence of proteinuria
and normal histology in many patients and
reported very low urine sodium concentrations -
findings of a prerenal type of uraemia.
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Ascites
Renal function varies enormously in patients
with ascites, values for glomerular filtration rate
and renal plasma flow showing a complete spec-
trum from twice normal down to those found
with significant renal impairment. When renal
failure is present, the markedly reduced filtra-
tion of sodium may be sufficient alone to explain
the fluid retention, but for those with well
preserved renal function other factors acting
on the renal tubules must be implicated. It
is possible to determine the nephron site for
abnormal sodium retention under conditions
of a maximum water diuresis. Although the
increased sodium reabsorption has been shown
to occur throughout the nephron the greatest
difference between patients with and without
sodium retention is in the distal segment (distal
convulted tubule or collecting tubule) (Fig 1).5
Hormonal and neural factors affecting this
part of the nephron include aldosterone, atrial
natriuretic hormone and the sympathetic
nervous system.
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
The concept has developed that cirrhosis is a
high renin high aldosterone state. This has not,
however, been confirmed in many studies in
which only 35-50% of patients accumulating
ascites have increased values (Fig 2)5-8 Further-
more, before there is clinical evidence for
fluid retention the renin-angiotensin-aldosterone
system has been reported to be suppressed.5 6
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Figure 1: Comparison ofthe role ofthe different nephron
segments in the pathogenesis ofabnormal sodium retention in
cirrhosis. These studies were carried out during a water diuresis
and all patients diluted their urine to <75 mosmollkg. From
Wilkinson et al (ref228). Reprinted with permissionfrom
Clinical Science. Copyright @ 1979 The Biochemical
Society, London.
In view of the normal values for aldosterone in
a number of patients actively retaining sodium
its pathogenic importance has been questioned.
Evidence in favour of a dominant role for aldo-
sterone include: (a) renal sodium excretion is
closely related to plasma concentration and the
renal excretion of aldosterone whatever the state
of sodium balance5; (b) blood volume, and
expression of renal sodium retention, correlates
well with the plasma aldosterone concentration9;
(c) the aldosterone antagonist spironolactone or
adrenalectomy will almost invariably reverse the
sodium retention, provided renal failure is not
already present'° "; (d) during P-adrenergic
blockade it was observed that the renal sodium
excretion increased or decreased exactly as pre-
dicted by the changes in aldosterone.'2 Thus if
aldosterone is of major importance one must
implicate an increase in renal tubular sensitivity
to this hormone. It is of further interest that the
abnormal aldosterone/sodium excretion relation-
ship is 'shifted to the left' compared with control
subjects and this becomes more marked with
advanced disease.9
ATRIAL NATRIURETIC PEPTIDE
It is now established that a 28 amino acid peptide
(atrial natriuretic peptide) synthesised by the
atrial wall has a major role in the regulation of
sodium excretion. It is released in response to
central volume expansion. Atrial natriuretic pep-
tide concentrations in cirrhosis are variable, but
most studies have shown plasma values to be
increased or normal when ascites is present."' 14
Furthermore, in contrast with aldosterone, there
appears to be a reduced renal sensitivity to its
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Figure 2: Plasma renin activity and aldosterone
in patients with cirrhosis and without clinical ev
retention. Stippled areas indicate the normal ran
from Wilkinson et al[216, 223, 2281(1977-79
natriuretic effects.'5 16 Whether thi
insensitivity or down regulation of
remains to be determined.
SYMPATHETIC ACTIVITY
Increased renal sympathetic activity
sodium reabsorption. Plasma noradre
centrations (an indirect index of s3
activity) are raised in cirrhotics with a
are inversely related to sodium excreti
recent studies in cirrhotic animal m
shown marked amelioration of sodiun
when the renal sympathetic system
vated. 1"
WATER RETENTION
The kidney retains water secondary tc
order to maintain osmotic equilibri
ascites, however, excess water is
retained resulting in hyponatraer
studies point to increased antidiureti
levels as the dominant pathogenic
Recent studies using a thromboxane
inhibitor have suggested that this
may also affect renal water excretion ir
with ascites.20
Synthesis of available data relating t
pathogenesis of ascites
Ascitic fluid is derived from he
splanchnic lymph, the formation
* increases consequent to portal hypertension, and
accentuated by hypoalbuminaemia. Tradition-
ally renal sodium and water retention is thought
of as a homeostatic mechanism to restore
'effective' extracellular fluid volume and blood
* volumes (the components available to the intra-
thoracic volume receptors). The initial deficits
were said to arise as a result of loss of extra-
cellular fluid into the peritoneal compartment as
ascites, and from sequestration of blood in the
splanchnic circulation secondary to portal hyper-
s tension. It is now realised, however, that sodium
: retention precedes ascites formation.2' This con-
cept has therefore been modified with peripheral
vasodilatation, characteristic of many patients
with cirrhosis, as the initiating factor causing a
low effective arterial blood volume.22 The site of
vasodilatation is likely to be the splanchnic
circulation and/or that supplying the skin and
muscles. Although this 'underfill' concept may
indeed be valid for the one-third of patients
with a stimulated renin-angiotensin-aldosterone
system it is incompatible with the findings of
normal values for those with normal plasma
aldosterone, and with increased plasma atrial
natriuretic peptide. In order to explain the
mechanisms involved in the other patients a
number of findings must be taken into account.
These include suppression of the renin-angio-
ernze et al tensin system before clinical evidence of fluid
concentration retention, and possible altered renal tubular
,idence offluid sensitivity to aldosterone and atrial natriuretic
rge. Modified peptide.
)- Consideration of patients before ascites has
developed may help interpretation. Whatever its
explanation the aldosterone/sodium excretion
is is true relationship is abnormal at this stage of the
f receptors disease and sodium excretion appears to be
related to aldosterone. Presumably, as the
abnormality develops the previously normal
aldosterone levels result in some degree of
fluid retention which account for the expanded
promotes plasma volume observed at this stage of the
naline con- disease. If the fluid remains within the 'effective'
ympathetic compartments this could explain the suppression
iscites, and of the renin-angiotensin-aldosterone system
ion. 17 More which would result in a return to sodium balance
todels have at a higher concentration of total body sodium.
n retention The process would be accentuated by reduced
i is dener- renal sensitivity to atrial natriuretic hormone.
An alternative explanation to the traditional
concept for ascites formation is 'the overflow
theory.'23 Renal sodium and water retention are
said to be the primary abnormalities with the
sodium in expanded extracellular fluid localising to the
ium. With peritoneal cavity when factors such as portal
sometimes hypertension and reduced plasma oncotic
nia. Most pressure favour ascites formation. For the
ic hormone 35% of patients in whom the renin-angiotensin-
- factors.'9 aldosterone system is not stimulated and
k2 synthase natriuretic hormone concentrations are in-
compound creased the findings fit well with this concept.
n cirrhotics There is evidence that splanchnic haemo-
dynamics may be fundamentally different for
these two groups of ascitic patients. In one study
patients were divided into those readily respond-
o the ing to diuretics without complication and those
with resistant ascites is which diuretics readily
patic and precipitated renal impairment.24 Although the
of which components of the renin-angiotensin-aldo-
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sterone system were not specifically determined
one might predict that the diuretic responsive
group are more likely to have ascites forming as
an overflow mechanism than those in whom the
effective extracellular fluid was already depleted
(diuretics in the latter group presumably result-
ing in further depletion with renal impairment
and thus diuretic resistance). Those comprising
the latter group had significantly less spontan-
eous portasystemic shunting and a tendency to
a higher postsinusoidal vascular resistance. The
authors concluded that collateral vascular resist-
ance must also be higher. Taken together these
changes would encourage intrahepatic lymph
formation with consequent accumulation of
ascites. Thus, ascites would be developing as
a primary abnormality independent of the effec-
tive extracellular fluid volume which eventually
falls.
Hepatorenal syndrome
The aetiology of hepatorenal syndrome is still
incompletely understood. To date most empha-
sis has centred on the hypothesis that it is caused
by severe renal arterial and arteriolar vasocon-
striction causing reduced renal blood flow and
thence renal failure. This has been based on
many studies which have shown reduced renal
blood flow, but was given extra impetus by those
of Epstein et al in which renal angiography
showed marked vasoconstriction of the arterial
vasculature.2' Studies by Ring-Larsen and
others, however, have shown that many patients
with ascites but relatively intact renal function
have renal blood flows comparable with those
observed in many subjects with hepatorenal
syndrome.26 This suggests that other factors
modulating glomerular filtration rate must be
important.2728 This is likely to involve mesangial
cells which have similar properties to smooth
muscle. These cells invaginate the glomerular
capillary tuft and contract in response to many
mediators. Mesangial cells appear to dynamic-
ally regulate the surface area available for ultra-
filtration, and thus the ultrafiltration co-
efficient.2526
Renal blood flow is dependent on renal
vascular resistance and renal perfusion pressure
(mean arterial pressure minus renal venous
pressure). Many patients with decompensated
liver disease have a moderately low mean arterial
pressure, and increased renal venous pressure.
Furthermore, liver failure is characterised by
increased sympathetic tone which appears to
shift the autoregulatory curve such that renal
blood flow is more dependent on renal perfusion
pressure. Thus, even patients with a modest
decrease in renal perfusion pressure may exhibit
a significant fall in renal blood flow. No studies
constructing a scattergram of the perfusion
pressure/renal blood flow relationship in patients
with liver disease or hepatorenal syndrome have
yet been carried out.
MECHANISMS FOR VASOCONSTRICTION
Most research over the last 10-20 years has
focused on identifying increased production of
vasoactive mediators of vasoconstriction. Inter-
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Figure 3: Relationship ofhepatorenal syndrome to
endotoxaemia as measured by the limulus assay. From
Wilkinson et al (ref220). Reprinted with kind permission
from the British Medical Journal. Copyright @ 1976.
estingly, many of these mediators also modulate
mesangial cell function, causing contraction of
this smooth muscle like cell, and may therefore
modulate not only renal blood flow through the
arterioles but also through the glomerular
capillary bed.
PERIPHERAL ARTERIAL VASODILATATION
HYPOTHESIS
The most recent proposal to explain renal vaso-
constriction is the vasodilatation hypothesis of
Schrier et al,22 and suggests that systemic vaso-
dilatation is the initiating event. This, in its
extreme form results in a reduction of effective
arterial blood volume with moderate hypoten-
sion. The cause of systemic vasodilatation is
unknown, but recent studies on the role of
endothelium derived relaxing factor (nitric
oxide) in animal models of cirrhosis have sug-
gested that this may be an important factor.29
Systemic vasodilatation activates homeostatic
mechanisms causing rises in plasma renin, aldos-
terone, noradrenaline, and vasopressin concen-
trations which cause sodium retention and renal
vasoconstriction. Procedures which augment
plasma volume, such as head out of water
immersion or plasma expansion, result in a
small transient increase in renal blood flow and
glomerular filtration rate in many subjects, but
this is rapidly offset by redistribution of fluid or
enhanced vasodilatation. Fernandez-Seara et al
have reported an interesting study in which they
observed a decrease in systemic vascular resist-
ance, a decrease in renal blood flow, and in
patients with ascites there was an initial increase
in femoral blood flow (to twice normal), indica-
tive of participation of the extra-splanchnic
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system in the vasodilatation.38 On the other
hand, patients with hepatorenal syndrome
exhibited femoral blood flow close to normal
subjects suggesting that splanchnic vasodilata-
tion was extreme causing intense activation of
the pressor systems.
There is marked activation of the sympatho-
adrenal system in advanced liver disease, and
the degree of activation follows the degree of
decompensation.3' The kidneys are richly in-
nervated by the sympathetic system which,
when activated, increase renal vascular resist-
ance. Early studies of a-adrenergic blockade by
phentolamine infusion produced no improve-
ment in renal function, although any beneficial
effect was offset by a fall in mean arterial
pressure.32 More recently, a novel approach has
used lumbar sympathetic blockade of the sym-
pathetic nerves, which produced an increase in
renal blood flow in all eight subjects studied, but
only five subjects showed an improvement in
glomerular filtration rate, and three showed an
actual deterioration.33 Thirdly, studies in which
head out ofwater immersion have followed serial
changes in glomerular filtration rate and plasma
noradrenaline concentrations did not observe
suppression of noradrenaline in nine out of 15
subjects in whom there was an improvement
in glomerular filtration rate.34 Thus, increased
sympathetic activity may be an important factor
reducing glomerular filtration rate in some but
not all patients with hepatorenal syndrome.
As already discussed the renin-angiotensin
system is activated in decompensated liver
disease.6'8 Increased renin formation may be
secondary to renal hypoperfusion or a decrease
in effective blood volume. Activation of renin
formation increases angiotensin II formation
within the kidney. Angiotensin II predomin-
antly increases efferent arteriolar tone and thus
the filtration fraction. Although this reduces
renal blood flow and increases renal vascular
resistance, it maintains glomerular filtration
rate. Thus, in conditions such as hypovoalemia
or shock, it is often regarded as a mechanism
protecting glomerular filtration rather than the
converse. This important principal was demon-
strated by Schroeder et al who infused angio-
tensin II into patients with cirrhosis.35 This study
observed that in four of five patients with the
lowest renal blood flow there was an actual
increase in glomerular filtration rate despite a
further fall in renal blood flow.
CIRCULATING OR INTRARENAL VASOCONSTRICTOR.
ROLE OF ENDOTOXINS
Although activation of the above homeostatic
mechanisms are undoubtedly responsible for
some degree of renal vasoconstriction other
factors are likely to be important.
Endotoxins are the lipopolysaccharide com-
ponents of the cell wall of gram negative bacilli.
They are thought to be responsible for many of
the manifestations of gram negative septicaemia
in man, and are known to be vasoconstrictor in
the renal circulation in animals. In advanced
liver disease, there appears to be failure of the
reticuloendotheliac system to remove endotoxins
absorbed from the gut, and direct absorption
through portasystemic collaterals into the
systemic circulation. Several studies have shown
a higher incidence of endotoxaemia in the sys-
temic circulation in hepatorenal syndrome36 38
(Fig 3). Other toxins such as staphylococcal
toxin may act synergistically with endotoxins
and may account for some of the discrepant
results reported by other groups. Supportive
evidence is also provided by more recent studies
in which daily culture of blood, urine, sputum,
ascites, as well as daily nasopharyngeal/vaginal
swabs, have shown a higher incidence of bac-
terial infection and fungal infection in patients
with fulminant hepatic failure developing hepa-
torenal syndrome.39
If endotoxins or indeed other bacterial toxins
are important in the pathogenesis of hepatorenal
syndrome, what is the mechanism? Several lines
of investigation have shown that endotoxins
activate formation of the eicosanoids. This is
either through a direct effect on circulating
monocytes or tissue resident macrophages.
Eicosanoids comprise in part the prostaglandins,
thromboxane A2, and the cysteinyl-leukotrienes
(LTC4, LTD4, and LTE4). These may be classi-
fied into renal vasodilators (PGE2, and prosta-
cyclin) and renal vasoconstrictors (TXA2, and
LTC4 and LTD4), as well as causing relaxation
or contraction of the mesangium respectively.
The role of thromboxane A2 is controversial.
Some studies have reported increased renal pro-
duction while others have suggested that there is
normal or decreased production of thromboxane
A2 as assessed by urinary excretion rate or
concentration of its stable metabolite TXB2
(40-43). More recent studies have suggested that
while there is increased renal and systemic
production of thromboxane A2 in hepatorenal
syndrome,"4 this was not significantly greater
than that in subjects appropriately controlled
for severity of hepatic dysfunction but with
relatively normal renal function. Thus,
increased production appears to primarily reflect
the severity of liver disease.
The vasodilatory prostaglandins are important
in maintaining renal function in patients with
decompensated liver disease. Renal production
of PGE2 and prostacyclin is increased in patients
with ascites,31 41 43 and several studies have shown
that administration of non-steroidal anti-
inflammatory drugs to such subjects causes
a marked reduction in glomerular filtration
rate.445 Studies have shown that urinary excre-
tion of PGE2 is decreased in hepatorenal syn-
drome. This may indicate decreased renal
production of this prostanoid or may reflect
glomerular filtration rate dependent excretion.
Recent immunocytochemistry studies suggest,
however, that medullary endoperoxide synthase
was decreased in renal biopsy samples from
subjects with hepatorenal syndrome compatible
with decreased production.' There is no good
evidence, however, to suggest that decreased
production of prostacyclin is responsible for
hepatorenal syndrome.44
Two studies have now shown increased
cysteinyl-leukotriene production in hepatorenal
syndrome.2847 Cysteinyl-leukotrienes are pro-
duced by inflammatory cells, lung, vascular
tissue, and probably kidney. We recently re-
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300- ported markedly increased cysteinyl-leukotriene
. production in hepatorenal syndrome compared
200- with appropriate controls suggesting that leuko-
trienes may be important in the aetiology of this
<x5 - - condition28 (Fig 4).
] Other mediators such as adenosine may also
X 100 * be important because this may cause systemic
o j vasodilatation and renal vasoconstriction.
m 65- Synthesis may be increased by tissue hypoxia
which is well recognised in advanced liver
o - failure. Recent studies with dipyridamole (which
f inhibits adenosine uptake) in cirrhotic patients
a 60- have shown that this compound produces renal
w impairment suggesting that this may also be an
important mediator.41 Studies with theophylline40
.(an adenosine antagonist) in cirrhotic patients,*
. however, showed little systemic effect.49 Trials
20- .. using the newer and more specific adenosine
g.§ * | * antagonists are needed. Platelet activating factor
0 *;' - . and endothelin are also potent modulators ofNorm CLD Asc Sev hep HRS CRF renal function, and studies on these are awaited
Clinical group with interest.
Figure 4: Urinary L TE4excretion in decompensated liver Thus, current concepts on the aetiology of
disease and hepatorenal syndrome. Highest values were
observed in hepatorenal syndrome, indicative of increased hepatorenal syndrome are that it iS a multifac-
production. CLD=compensated liver disease. torial condition caused by reduced renal blood
Asc=Ascites. Sev hep=Severe hepaticfailure. flow and altered ultrafiltration coefficient as a
CRF=Chronic renalfailure.
Reprinted by courtesy ofJ Hepatol (Ref44). result of mesangial cell contracton. Reduced
renal blood flow is caused by a moderate decrease
in renal perfusion pressure caused by systemic8ctive Sympathetict vasodilatation and increased renal venous pres-
3 Volumef dIrive sure. This is probably exacerbated by a shift in
the renal autoregulatory curve because of in-
creased sympathetic activity. This, together with
increased renovascular resistance and mesangial
eral il|cell contraction induced by a combination of
endotoxaemia, altered eicosanoid production,
and possibly increased adenosine production
v , gives rise to the functional renal impairment
inini * - 2 Renal afferent known as hepatorenal syndrome (Fig 5).+<arteriole constriction
Unresolved problems
The most intriguing unresolved issue relating
ins/'/Renin t to renal sodium retention is the apparently(ijnss l / / retention increased renal tubular sensitivity to
xins ?/Aaldosterone, apparent resistance to atrial
natriuretic hormone, and the mechanisms
underlying the peripheral vasodilatation.
Clarification of these abnormalities might be
A \1 t A ldos erone fundamental to understanding the initiation
rD ..-tAldos/erone! of sodium retention. Further clarification of
splanchnic haemodynamic changes is also
required. In particular whether there really are
Renal efferent
fundamental differences between patients who)\(g/ PGE2/PG12 Renal etferent might form ascites as an 'overflow' mechanism
from those who appear to have effective
central hypovolaemia. Longitudinal studies are
required to establish whether the former group
Glomerular 0 Filtrationt progresses to the latter or vice versa.
filtration rate fraction With respect to hepatorenal syndrome the role
of reduced renal perfusion pressure needs
further evaluation, and accurate data on the renal
blood flow/pressure relationship in liver disease
I ~~~~~~willbe fundamental to this area. More definitive
Figure5: This extends the perip
interrelationships between toxin.
their potential modulatory role ii
ATII=angiotensin II.
Hepatorenal studies on the role of cysteinyl-leucotrienes using
syndrome specific LTD4 antagonists are needed, and the
role of other mediators of increased vascular tone
Pheral vasodilatation hypothesis and illustrates the possible and mesangial cell function such as endothelin
slendotoxins as well as other horrnones and the eicosanoids and
renal haemodynamics and glomerular function. and plateletactivatig factor may also turn out tobe important contributory factors.
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